Differentiation of subgroups of monosymptomatic enuresis according to prepulse inhibition of the startle reflex

Acta Paediatr. 2012 Jul;101(7):e304-8. doi: 10.1111/j.1651-2227.2012.02624.x. Epub 2012 Feb 23.

Abstract

Aim: Monosymptomatic enuresis (ME) is a common disorder in children with serious social and psychological consequences. Treatment is usually initiated with desamino-arginine vasopressin (dDAVP) and/or alarm therapy as first-line treatment and imipramine as second-line. All treatments have proven efficacy, but are not successful with all patients. Therefore, a differentiation into subgroups according to treatment efficacy would be beneficial.

Methods: A group of patients resistant to first-line treatment was treated with imipramine and compared with matched controls successfully treated with dDAVP and/or alarm therapy. Prepulse inhibition (PPI) to acoustic startle reflexes was measured in all patients.

Results: In a group of 23 nonresponders, the median PPI was 72% (range 43-94%) compared with the matched dDAVP/alarm - responders with a median PPI of 26% (range 0-61%) (p < 0.0001). The response rate to imipramine was 87%.

Conclusion: The presented data provide evidence that PPI allows to identify two subgroups of ME. The results offer further insight into (at least) two different pathomechanisms involved in ME: (i) a maturational delay of reflex inhibition with reduced PPI and (ii) a normal PPI, possibly with abnormal sleep patterns, that can be influenced by imipramine.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Acoustic Stimulation
  • Adolescent
  • Adrenergic Uptake Inhibitors / therapeutic use
  • Antidiuretic Agents / therapeutic use
  • Child
  • Clinical Alarms
  • Combined Modality Therapy
  • Deamino Arginine Vasopressin / therapeutic use
  • Female
  • Humans
  • Imipramine / therapeutic use
  • Male
  • Nocturnal Enuresis / etiology
  • Nocturnal Enuresis / psychology*
  • Nocturnal Enuresis / therapy
  • Prospective Studies
  • Reactive Inhibition*
  • Reflex, Startle*
  • Treatment Outcome

Substances

  • Adrenergic Uptake Inhibitors
  • Antidiuretic Agents
  • Deamino Arginine Vasopressin
  • Imipramine